Healthcare is broken in the USA – but Pharma can lead the way to a new sustainable model
As we enter a new decade, and an election year, the pressure has never been higher on the pharmaceutical industry to justify what we add to the cost of healthcare. Price control has become a bipartisan issue and across the wide-range of policy positions that are on the table in Fall 2020, one area is clear: the transition towards value-based care is inevitable.
Join 1200+ of pharma’s top decision-makers at eyeforpharma Philadelphia (April 15-16) – the largest commercial pharma conference in North America – where the industry will come together to define a better way forward.
With an exceptional speaker faculty spanning eight functional tracks - including digital and marketing, sales, access, patient, RWE and data and commercial – the agenda is packed full of real-life case studies and tailored to the attendees’ learning needs. This really is a must-attend for anyone involved in US pharma and we are very excited to be involved on the program.
· Ramona Sequeira, President, Takeda U.S.A
· Sebastian Guth, President, Americas, Bayer
· Ivan Cheung, CEO & President, Eisai Inc.
· Rob Scott, Chief Medical Officer, Abbvie
· Chris Leibman, SVP, Value and Access, Biogen
· Scott Howell, VP and Head, US Market Access, Pharmaceuticals, Novartis
With 100+ case studies showcased by the leading voices that are driving pharma forward, eyeforpharma is the top destination for making sure your company gets right to the forefront of innovation.